GT Biopharma, Inc. (GTBP)

GT Biopharma Earnings Call Transcripts

Fiscal Year 2026

• Biotech Resurgence: Platforms and Pipelines of Today's Innovators

  A modular NK cell engager platform is advancing through clinical trials for blood cancers, solid tumors, and autoimmune diseases, with promising efficacy and a strong safety profile. The technology leverages camelid nanobody innovation and targets vast oncology and autoimmune markets.

  Read full transcript →

Fiscal Year 2025

• H.C. Wainwright 27th Annual Global Investment Conference

  Trispecific killer cell engager nanobodies are advancing in clinical trials for blood cancers, with a new focus on solid tumors and autoimmune diseases. The platform's unique IL-15 component drives NK cell proliferation, and preclinical data show strong efficacy in both hematologic and solid tumor models.

  Read full transcript →

Data Source: Quartr Last updated: Apr 16, 2026

Earnings call transcripts are provided by Quartr and are published within hours after each earnings call.

Update frequency:

Quarterly

Data Sources Report a data error

Stock Analysis Pro

Upgrade now for unlimited access to all data and tools.

Market Newsletter

Get a daily email with the top market news in bullet point format.